Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473188 | 1.00 | FDPS (0.49) | FDPSACHERXRABCHEAPP | |
| SCHEMBL6477392 | 0.95 | FDPS (0.51) | FDPSACHERXRABCHEAPP | |
| SCHEMBL6477393 | 0.95 | FDPS (0.51) | FDPSACHERXRABCHEAPP | |
| SCHEMBL6473193 | 0.90 | RXRA (0.51) | ACHERXRACNR2MEN1KMT2A | |
| SCHEMBL6473191 | 0.90 | RXRA (0.51) | ACHERXRACNR2MEN1KMT2A | |
| SCHEMBL6476811 | 0.90 | FDPS (0.53) | FDPSACHERXRABCHEMAOB | |
| SCHEMBL6476815 | 0.90 | FDPS (0.53) | FDPSACHERXRABCHEMAOB | |
| SCHEMBL6472649 | 0.87 | RXRA (0.54) | FDPSACHERXRABCHEAPP | |
| SCHEMBL6472653 | 0.87 | RXRA (0.54) | FDPSACHERXRABCHEAPP | |
| SCHEMBL6472405 | 0.87 | KDM4E (0.47) | FDPSRXRAAPPHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924388-B2 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-02 | — | — | US | disclosed |
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-05-13 | — | — | US | disclosed |
| US-6632963-B1 | Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2003-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | AHR, TYR, MC1R | FDPS 3696/4885ACHE 2858/4885RXRA 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.